For example, work on stroke has shown that MCP1 deficiency reduces infarct size (Hughes et al., 2002) and BBB breakdown (Strecker et al., 2013), while MCP1 overexpression exacerbates tissue damage (Chen et al., 2003). This evidence concerns the gene CCL2 and stroke disorder.